Back

Comparative safety and effectiveness of rivaroxaban and apixaban in patients with venous thromboembolism - a Danish nationwide study

29 August 2017 (10:05 - 10:55)
Organised by:
Congress Presentation Part of: What is new in venous thromboembolism? Acute pulmonary embolism ESC Premium Access ESC Congress 2017

About the speaker

Photo
Ms Caroline Sindet-Pedersen

Gentofte Hospital - Copenhagen University Hospital, Hellerup (Denmark)

6 More presentations in this session

Presentation thumbnail
Long-term effects of unprovoked venous thromboembolism on mortality and major cardiovascular events
Doctor W. Chang (Tainan, TW)
Abstract Slides
Presentation thumbnail
Validation of the prognostic impact of copeptin in normotensive pulmonary embolism in a european multicentre study.
Doctor K. Hellenkamp (Goettingen, DE)
Abstract Slides
Presentation thumbnail
A novel experimental in vivo model of acute pulmonary embolism
Doctor J. Schultz (Aarhus, DK)
Abstract Slides
Presentation thumbnail
The YEARS algorithm for suspected pulmonary embolism leads to much shorter diagnostic turnaround time than conventional algorithms
Doctor E. Klok (Leiden, NL)
Abstract Slides
Presentation thumbnail
Recurrent venous thromboembolism and major bleeding in patients treated with rivaroxaban or warfarin for venous thromboembolism in routine practice
Doctor C. Coleman (Storrs, US)
Abstract Slides

Access the full session

Session thumbnail
What is new in venous thromboembolism?

The Event

Event poster

ESC Congress 2017

29 August 2017 10:05 CET

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources